53 results about "Diseases outcome" patented technology

Models for the systemic inflammatory response to infection, which involve the use of immunocompromised animals, and methods of using the models are described. These models can be used in identifying analytes or biomarker panels that can be used in staging or monitoring sepsis. The models can also be used for predicting an animal's disease outcome or in providing a prognosis for sepsis patients. Further, the invention relates to methods for evaluating potential treatments for sepsis.

An SLC18A2 gene serves as a marker of prostate cancer. Methods are provided for diagnosing prostate cancer, predicting or prognosticating the disease outcome, predicting recurrence following surgery, and monitoring disease progression in an individual having prostate cancer. The methods relate to determining the methylation state of an SLC18A2 gene and/or determining the level of transcription or translation of the gene in a sample from the individual. Methods of treating prostate cancer are also provided. The invention also pertains to compositions and kits for use in the methods.

The invention relates to the technical field of biomedical diagnostics and discloses a reagent kit for detecting a serum marker of primary hepatic carcinoma, which consists of an ELISA plate enveloped by antigens, an enzyme-labeled antibody working solution, a sample diluent, a washing liquid, positive and negative control serum, a chromogenic solution and a stopping liquid. The reagent kit is characterized in that the envelope antigens of the ELISA plate are five groups of peptide antigens L4-A and L4-B; L7-B; L11-1, L11-3 and L11-4; L12-A and L12-B; and Sui1-A and Sui1-B, which correspond to five serum marker antibodies of the primary hepatic carcinoma; and Sui1-A and Sui1-B respectively. Except the L7B which is separately enveloped, each group of all the other groups of peptide antigens is enveloped by proportionally mixing polypeptides in the same group. Proven by evaluation experiments of the reagent kit and clinical trial, the reagent kit has good specificity and sensitivity, and can be used for early warning prompt or early diagnosis before the primary hepatic carcinoma appears or at early stage of the primary hepatic carcinoma, thereby improving the survival rate of carcinoma patients and evaluating treatment effect and disease outcome in time by observing the dynamic change of related indicators of the serum.

The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of Akt1, Akt2, and Akt3. The methods and kits also allow prediction of disease outcome and staging of patients with regard to therapy.

Disclosed are systems and methods for predicting patient response to a treatment option. In one embodiment, the image slides from patient tissue samples are divided into patches and morphological patterns correlated with a disease outcome are labeled and given a patch-level score, based on whether the morphological patterns occur only in patients with good outcomes or patients with poor outcomes. A patient-level score can be generated based, at least partly, on the patch-level scores. Patch-level scores can identify regions of interest for targeted biomarker identification.

The invention relates to a model for evaluating gastric cancer prognosis based on Lauren typing and postoperative residual lymph nodes and application, and belongs to the technical field of biomedical detection. According to the invention, the number of residual lymph nodes after Lauren typing and neoadjuvant chemotherapy is comprehensively used as a prognosis evaluation index after neoadjuvant chemotherapy of gastric cancer, and a prognosis evaluation model for patients after neoadjuvant chemotherapy of gastric cancer is established. Through clinical verification, the evaluation model can effectively pre-judge disease outcome after neoadjuvant chemotherapy of gastric cancer, and is more accurate than the traditional Japan JGCA standard and German Becker standard. The invention provides reference information for prognosis of tumor patients, so that clinical doctors are helped to formulate the most reasonable diagnosis and treatment plan for the tumor patients, and timely and effective doctor-patient communication is facilitated.

Ovarian, cervical cancer, endometriosis, clear cell renal carcinoma cancers are very heterogeneous diseases which lack robust diagnostic, prognostic and predictive clinical biomarkers. Conventional clinical biomarkers (stages, grades, tumor mass etc) and molecular biomarkers (CA125, KRAS, p53 etc) are not appropriate for early diagnostics, differential diagnostics, prediction and prognosis of the disease outcome for individual patients. The most common type of the human ovarian cancers is human epithelial ovarian cancer (EOC). This cancer is characterized with one of the lowest survival rates compared to other cancers. The present invention relates to an in vitro method for diagnosing epithelial ovarian cancer, cervical cancer, endometriosis, dear cell renal carcinoma and/or predisposition to epithelial ovarian cancer in a subject, the method comprising determining in a sample of the subject gene expression level of at least one gene in the MDS1 and EVI1 complex (MECOM) locus; and/or copy number of at least one gene in the MECOM locus; wherein the level against at least one expression cutoff value and/or copy number against at least one copy number cutoff value are indicative of the subject having epithelial ovarian cancer, cervical cancer, endometriosis, clear cell renal carcinoma and/or a predisposition to epithelial ovarian cancer, cervical cancer, endometriosis, dear cell renal carcinoma and/or determining whether the ovarian cancer in the subject is primary or secondary ovarian cancer and/or a risk of the disease progression after surgery treatment, and/or an effectiveness of post-surgery chemotherapy.